Probiotics study
This article was originally published in The Tan Sheet
Executive Summary
Administration of probiotics in patients with predicted severe acute pancreatitis must be regarded as unsafe, according to research published in The Lancet online Feb. 14. Conducted by Hein Gooszen, University Medical Center, Utrecth, Netherlands, et al., the double-blind, placebo controlled trial involved 296 patients with predicted severe acute pancreatitis - 152 were in the probiotics group and 144 in the placebo group. The probiotic preparation or placebo was administered directly to subjects' digestive tract twice daily for two weeks. Researchers found infectious complications in about 30 percent of patients in both groups. While 16 percent of the probiotics group patients died, 6 percent in the placebo group died. "Our findings show that probiotics should not be administered routinely in patients with predicted severe acute pancreatitis, and that the particular composition used here should be banned for the present indication," Gooszen et al. note. "Most importantly, probiotics can no longer be considered to be harmless adjuncts to enteral nutrition, especially in critically ill patients or patients at risk for non-occlusive mesenteric ischaemia"...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.